文献速递消化道肿瘤与早癌

基于国际错配修复联盟数据的林奇综合征诊断与管理全球实践模式

Worldwide Practice Patterns in Lynch Syndrome Diagnosis and Management, Based on Data From the International Mismatch Repair Consortium.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-04-24

研究通过国际错配修复联盟(IMRC)对21个国家63家成员机构的55名提供者进行问卷调查,了解林奇综合征诊断与管理实践。结果显示病例发现、胚系分析、家庭信息传递和风险管理实践在全球范围内存在广泛异质性,仅28%对胚系分析未确认的疑似致病突变病例进行肿瘤双等位基因突变检测,35%推荐阿司匹林化学预防。

要点

  • 55%受访者报告对新诊断林奇综合征相关癌症患者开展常规广泛人群肿瘤检测,27%依赖临床标准结合选择性肿瘤和/或胚系分析。
  • 64%受访者使用多基因面板进行胚系分析,仅28%对胚系分析未确认疑似致病突变的病例检测肿瘤双等位基因突变。
  • 98%项目推荐每1至2年结肠镜检查,仅35%推荐阿司匹林化学预防。

核心结论

  • 全球IMRC成员机构对林奇综合征的管理实践存在广泛异质性,可能反映新兴技术的快速进展、区域资源差异以及许多临床问题缺乏确定性数据。

研究设计与样本

  • 研究收集了国际错配修复联盟(IMRC)的数据,该联盟由全球从事林奇综合征家族照护的主要研究和临床团队组成;邀请IMRC机构完成问卷以描述林奇综合征诊断和管理实践模式。
  • 来自21个国家128家成员机构中63家(49%)的55名提供者完成了问卷。

主要发现

  • 55%受访者报告在新诊断林奇综合征相关癌症患者中参与常规广泛人群肿瘤检测,27%报告依赖临床标准结合选择性肿瘤和/或胚系分析。
  • 64%受访者报告使用多基因面板进行胚系分析,仅28%报告对胚系分析未确认疑似致病突变的病例检测肿瘤双等位基因突变。
  • 受访者报告依赖被动传播信息给高危家庭成员,且基因检测推荐的执行存在差异。
  • 风险管理实践各异,几乎所有项目(98%)推荐每1至2年结肠镜检查,但仅35%推荐阿司匹林化学预防。

关键数值与推荐

  • 98%的项目推荐每1至2年结肠镜检查。
  • 35%的项目推荐阿司匹林化学预防。
  • 55%的受访者报告参与常规广泛人群肿瘤检测。
  • 27%的受访者报告依赖临床标准结合选择性肿瘤和/或胚系分析。
  • 64%的受访者报告使用多基因面板进行胚系分析,28%报告对胚系分析未确认疑似致病突变的病例检测肿瘤双等位基因突变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Families with a history of Lynch syndrome often do not adhere to guidelines for genetic testing and screening. We investigated practice patterns related to Lynch syndrome worldwide, to ascertain potential targets for research and public policy efforts. METHODS: We collected data from the International Mismatch Repair Consortium (IMRC), which comprises major research and clinical groups engaged in the care of families with Lynch syndrome worldwide. IMRC institutions were invited to complete a questionnaire to characterize diagnoses of Lynch syndrome and management practice patterns. RESULTS: Fifty-five providers, representing 63 of 128 member institutions (49%) in 21 countries, completed the questionnaire. For case finding, 55% of respondents reported participating in routine widespread population tumor testing among persons with newly diagnosed Lynch syndrome-associated cancers, whereas 27% reported relying on clinical criteria with selective tumor and/or germline analyses. Most respondents (64%) reported using multigene panels for germline analysis, and only 28% reported testing tumors for biallelic mutations for cases in which suspected pathogenic mutations were not confirmed by germline analysis. Respondents reported relying on passive dissemination of information to at-risk family members, and there was variation in follow through of genetic testing recommendations. Reported risk management practices varied-nearly all programs (98%) recommended colonoscopy every 1 to 2 years, but only 35% recommended chemoprevention with aspirin. CONCLUSIONS: There is widespread heterogeneity in management practices for Lynch syndrome worldwide among IMRC member institutions. This may reflect the rapid pace of emerging technology, regional differences in resources, and the lack of definitive data for many clinical questions. Future efforts should focus on the large numbers of high-risk patients without access to state-of-the-art Lynch syndrome management.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Pan JY, Haile RW, Templeton A, et al. Worldwide Practice Patterns in Lynch Syndrome Diagnosis and Management, Based on Data From the International Mismatch Repair Consortium. Clin Gastroenterol Hepatol. 2018. PMID: 29702294. doi:10.1016/j.cgh.2018.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。